192 related articles for article (PubMed ID: 10074939)
41. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
[TBL] [Abstract][Full Text] [Related]
42. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin.
Dunten P; Kammlott U; Crowther R; Levin W; Foley LH; Wang P; Palermo R
Protein Sci; 2001 May; 10(5):923-6. PubMed ID: 11316871
[TBL] [Abstract][Full Text] [Related]
43. Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity.
Finzel BC; Baldwin ET; Bryant GL; Hess GF; Wilks JW; Trepod CM; Mott JE; Marshall VP; Petzold GL; Poorman RA; O'Sullivan TJ; Schostarez HJ; Mitchell MA
Protein Sci; 1998 Oct; 7(10):2118-26. PubMed ID: 9792098
[TBL] [Abstract][Full Text] [Related]
44. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
45. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
Hanessian S; MacKay DB; Moitessier N
J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
[TBL] [Abstract][Full Text] [Related]
46. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
48. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction.
Knäuper V; Cowell S; Smith B; López-Otin C; O'Shea M; Morris H; Zardi L; Murphy G
J Biol Chem; 1997 Mar; 272(12):7608-16. PubMed ID: 9065415
[TBL] [Abstract][Full Text] [Related]
49. Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate.
Meng Q; Malinovskii V; Huang W; Hu Y; Chung L; Nagase H; Bode W; Maskos K; Brew K
J Biol Chem; 1999 Apr; 274(15):10184-9. PubMed ID: 10187802
[TBL] [Abstract][Full Text] [Related]
50. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
51. Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy.
Gonnella NC; Li YC; Zhang X; Paris CG
Bioorg Med Chem; 1997 Dec; 5(12):2193-201. PubMed ID: 9459017
[TBL] [Abstract][Full Text] [Related]
52. Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.
Sawa M; Kondo H; Nishimura S
Bioorg Med Chem Lett; 2002 Feb; 12(4):581-4. PubMed ID: 11844676
[TBL] [Abstract][Full Text] [Related]
53. Biochemical characterization of human collagenase-3.
Knäuper V; López-Otin C; Smith B; Knight G; Murphy G
J Biol Chem; 1996 Jan; 271(3):1544-50. PubMed ID: 8576151
[TBL] [Abstract][Full Text] [Related]
54. X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding.
Jozic D; Bourenkov G; Lim NH; Visse R; Nagase H; Bode W; Maskos K
J Biol Chem; 2005 Mar; 280(10):9578-85. PubMed ID: 15611040
[TBL] [Abstract][Full Text] [Related]
55. The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain.
Gomis-Rüth FX; Gohlke U; Betz M; Knäuper V; Murphy G; López-Otín C; Bode W
J Mol Biol; 1996 Dec; 264(3):556-66. PubMed ID: 8969305
[TBL] [Abstract][Full Text] [Related]
56. Analogue based design of MMP-13 (Collagenase-3) inhibitors.
Sarma JA; Rambabu G; Srikanth K; Raveendra D; Vithal M
Bioorg Med Chem Lett; 2002 Oct; 12(19):2689-93. PubMed ID: 12217355
[TBL] [Abstract][Full Text] [Related]
57. Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1).
Vincenti MP; Coon CI; Mengshol JA; Yocum S; Mitchell P; Brinckerhoff CE
Biochem J; 1998 Apr; 331 ( Pt 1)(Pt 1):341-6. PubMed ID: 9512498
[TBL] [Abstract][Full Text] [Related]
58. Specificity of binding with matrix metalloproteinases.
Gupta SP; Patil VM
Exp Suppl; 2012; 103():35-56. PubMed ID: 22642189
[TBL] [Abstract][Full Text] [Related]
59. Crystal structure of a Trimeresurus mucrosquamatus venom metalloproteinase providing new insights into the inhibition by endogenous tripeptide inhibitors.
Chou TL; Wu CH; Huang KF; Wang AH
Toxicon; 2013 Sep; 71():140-6. PubMed ID: 23732127
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
